Cargando…

Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer

BACKGROUND: The aim of this study was to analyze the frequency of Thyroid Transcription Factor (TTF)-1 expression in small cell lung cancer (SCLC) and its value for the diagnosis of SCLC, the response to first line treatment as well as the prognostic impact on overall survival (OS). METHODS: We anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Misch, Daniel, Blum, Torsten, Boch, Christian, Weiss, Timo, Crolow, Catharina, Griff, Sergej, Mairinger, Thomas, Bauer, Torsten T, Kollmeier, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391673/
https://www.ncbi.nlm.nih.gov/pubmed/25889870
http://dx.doi.org/10.1186/s13000-015-0250-z
_version_ 1782365856753254400
author Misch, Daniel
Blum, Torsten
Boch, Christian
Weiss, Timo
Crolow, Catharina
Griff, Sergej
Mairinger, Thomas
Bauer, Torsten T
Kollmeier, Jens
author_facet Misch, Daniel
Blum, Torsten
Boch, Christian
Weiss, Timo
Crolow, Catharina
Griff, Sergej
Mairinger, Thomas
Bauer, Torsten T
Kollmeier, Jens
author_sort Misch, Daniel
collection PubMed
description BACKGROUND: The aim of this study was to analyze the frequency of Thyroid Transcription Factor (TTF)-1 expression in small cell lung cancer (SCLC) and its value for the diagnosis of SCLC, the response to first line treatment as well as the prognostic impact on overall survival (OS). METHODS: We analyzed a total of 294 patients (m, n = 184; f, n = 110) with SCLC (stage IIIA, n = 32; IIIB, n = 87; IV, n = 175) diagnosed in our institution between January 2005 and December 2008. Patient’s characteristics comprising age, gender, histology and first line treatment were included into the analyses. For the follow-up of patients the governmental death registrar was used. The TTF-1 immunostaining was prospectively performed. CT scans of all patients were reviewed and response to treatment was evaluated using the Response Evaluation Criteria In Solid Tumors 1.0 (RECIST) criteria. RESULTS: A total of 221 of the 294 patients were eligible for analysis. Patients with TTF-1-positive SCLC had a median OS of 374 (95% CI 306–442) days. The OS of patients with TTF1-negative SCLC was 290 (95% CI 191–389) days, which was not significantly shorter (p = 0.254). Also stratification for tumor stage did not reveal significant difference in OS. Analyzing the disease control rate (DCR) in patients with metastatic disease (stage IV), we observed a significantly (p = 0.006) improved response to treatment in the group of patients with TTF-1-expression (DCR 86% vs. 56%). Regarding the overall response rates (ORR) in the entire population, there was no difference observed between both subgroups. (TTF-1-pos. 75.3% vs. TTF-1-neg. 71.4%; p = 0.642). CONCLUSIONS: The diagnostic information of TTF-1 in SCLC seems to be limited. TTF-1 had no prognostic value concerning OS, but may serve as a predictor for response to first line chemotherapy. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5811254651472285
format Online
Article
Text
id pubmed-4391673
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43916732015-04-10 Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer Misch, Daniel Blum, Torsten Boch, Christian Weiss, Timo Crolow, Catharina Griff, Sergej Mairinger, Thomas Bauer, Torsten T Kollmeier, Jens Diagn Pathol Research BACKGROUND: The aim of this study was to analyze the frequency of Thyroid Transcription Factor (TTF)-1 expression in small cell lung cancer (SCLC) and its value for the diagnosis of SCLC, the response to first line treatment as well as the prognostic impact on overall survival (OS). METHODS: We analyzed a total of 294 patients (m, n = 184; f, n = 110) with SCLC (stage IIIA, n = 32; IIIB, n = 87; IV, n = 175) diagnosed in our institution between January 2005 and December 2008. Patient’s characteristics comprising age, gender, histology and first line treatment were included into the analyses. For the follow-up of patients the governmental death registrar was used. The TTF-1 immunostaining was prospectively performed. CT scans of all patients were reviewed and response to treatment was evaluated using the Response Evaluation Criteria In Solid Tumors 1.0 (RECIST) criteria. RESULTS: A total of 221 of the 294 patients were eligible for analysis. Patients with TTF-1-positive SCLC had a median OS of 374 (95% CI 306–442) days. The OS of patients with TTF1-negative SCLC was 290 (95% CI 191–389) days, which was not significantly shorter (p = 0.254). Also stratification for tumor stage did not reveal significant difference in OS. Analyzing the disease control rate (DCR) in patients with metastatic disease (stage IV), we observed a significantly (p = 0.006) improved response to treatment in the group of patients with TTF-1-expression (DCR 86% vs. 56%). Regarding the overall response rates (ORR) in the entire population, there was no difference observed between both subgroups. (TTF-1-pos. 75.3% vs. TTF-1-neg. 71.4%; p = 0.642). CONCLUSIONS: The diagnostic information of TTF-1 in SCLC seems to be limited. TTF-1 had no prognostic value concerning OS, but may serve as a predictor for response to first line chemotherapy. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5811254651472285 BioMed Central 2015-04-02 /pmc/articles/PMC4391673/ /pubmed/25889870 http://dx.doi.org/10.1186/s13000-015-0250-z Text en © Misch et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Misch, Daniel
Blum, Torsten
Boch, Christian
Weiss, Timo
Crolow, Catharina
Griff, Sergej
Mairinger, Thomas
Bauer, Torsten T
Kollmeier, Jens
Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer
title Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer
title_full Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer
title_fullStr Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer
title_full_unstemmed Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer
title_short Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer
title_sort value of thyroid transcription factor (ttf)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391673/
https://www.ncbi.nlm.nih.gov/pubmed/25889870
http://dx.doi.org/10.1186/s13000-015-0250-z
work_keys_str_mv AT mischdaniel valueofthyroidtranscriptionfactorttf1fordiagnosisandprognosisofpatientswithlocallyadvancedormetastaticsmallcelllungcancer
AT blumtorsten valueofthyroidtranscriptionfactorttf1fordiagnosisandprognosisofpatientswithlocallyadvancedormetastaticsmallcelllungcancer
AT bochchristian valueofthyroidtranscriptionfactorttf1fordiagnosisandprognosisofpatientswithlocallyadvancedormetastaticsmallcelllungcancer
AT weisstimo valueofthyroidtranscriptionfactorttf1fordiagnosisandprognosisofpatientswithlocallyadvancedormetastaticsmallcelllungcancer
AT crolowcatharina valueofthyroidtranscriptionfactorttf1fordiagnosisandprognosisofpatientswithlocallyadvancedormetastaticsmallcelllungcancer
AT griffsergej valueofthyroidtranscriptionfactorttf1fordiagnosisandprognosisofpatientswithlocallyadvancedormetastaticsmallcelllungcancer
AT mairingerthomas valueofthyroidtranscriptionfactorttf1fordiagnosisandprognosisofpatientswithlocallyadvancedormetastaticsmallcelllungcancer
AT bauertorstent valueofthyroidtranscriptionfactorttf1fordiagnosisandprognosisofpatientswithlocallyadvancedormetastaticsmallcelllungcancer
AT kollmeierjens valueofthyroidtranscriptionfactorttf1fordiagnosisandprognosisofpatientswithlocallyadvancedormetastaticsmallcelllungcancer